About Us

Corvus is a clinical-stage biopharmaceutical company developing novel therapies with the potential to significantly improve the treatment of immune diseases and cancer. Our lead program, soquelitinib, is a first-in-class, oral therapy that selectively inhibits ITK to modulate and control parallel signaling pathways in the immune system.

Our seasoned team of biopharma industry leaders are dedicated to developing new medicines for patients in need. Their successful track record of discovering, developing and commercializing innovative therapies for patients with serious diseases includes inventors and scientists who developed the anti-cancer and auto-immune disease medicines, Rituxan (rituximab), Imbruvica (ibrutinib) and Zelboraf (vemurafenib). The development of ITK inhibition, which targets the modulation of parallel signaling pathways for T cells and the immune system, is a significant opportunity that parallels Rituxan (targeting CD20) and Imbruvica (targeting BTK), both of which modulate B cells.

Founded in 2014, Corvus has developed a deep pipeline of potentially breakthrough investigational medicines designed to be potent, selective and convenient to administer. The Company is focused on the advancement of its ITK inhibitor, soquelitinib, and is working with partners to advance its other clinical stage programs.

We believe in putting patients first. With that in mind, we report our preclinical and clinical data promptly and frequently at major scientific meetings, so our research can be used by others to advance medicine for the benefit of patients.